FDA regulatory strategy is the critical path between product development and commercial launch for every orthopedic medical device. The choice between 510(k) clearance, De Novo classification, and PMA approval — and the increasingly important Breakthrough Device Designation pathway for novel technologies including surgical robots and AI-enabled devices — directly determines development timelines, clinical evidence requirements, and competitive barriers to entry.
Topics Covered
• 510(k) Clearance Process
• PMA Approval — Requirements and Timeline
• De Novo Classification
• Breakthrough Device Designation
• Predicate Device Strategy
• FDA Orthopedic Device Panel
• Post-Market Surveillance Requirements
Table of Contents
1. Executive Summary
2. Landscape Overview
3. 510(k) Clearance Process
4. PMA Approval — Requirements and Timeline
5. De Novo Classification
6. Breakthrough Device Designation
7. Predicate Device Strategy
8. FDA Orthopedic Device Panel
9. Post-Market Surveillance Requirements
10. Strategic Conclusions and Recommendations
11. Appendix
List of Tables
Table 1. Overview and Key Data 2025
Table 2-8. Topic-Specific Analysis Tables
Table 2. Leading Suppliers — Strategy Assessment 2025
Table 3. Key Risks and Mitigation Strategies
Companies Profiled
Aesculap
Arthrex
DePuy Synthes
Enovis
Globus Medical
NuVasive
Smith & Nephew
Stryker
Wright Medical
Zimmer Biomet
